Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement